<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805452</url>
  </required_header>
  <id_info>
    <org_study_id>2014-RdC-PRO-Th</org_study_id>
    <secondary_id>2014-004296-22</secondary_id>
    <nct_id>NCT02805452</nct_id>
  </id_info>
  <brief_title>Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer</brief_title>
  <acronym>VesiCaP</acronym>
  <official_title>Impact of Solifenacin Succinate for Treatment of Acute Irritative Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Succinate of Solifenacin reduces the&#xD;
      OverActive Bladder syndrome occurring during prostate irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter Phase III, randomized, double-blinded, parallel group placebo-controlled study.&#xD;
&#xD;
      2 groups:&#xD;
&#xD;
        -  Control arm = pts. with placebo&#xD;
&#xD;
        -  Experimental arm = pts. with Solifenacin succinate 5 mg - Vesicare® All patients with an&#xD;
           OAB sub-score using the USP scale greater to 5 during prostate cancer radiotherapy will&#xD;
           be included, receiving either a placebo or Solifenacin succinate (5mg) for duration of 3&#xD;
           months.&#xD;
&#xD;
      The randomization will be stratified on the radiotherapy dose (1 to 40 Gy or 40 to 70/80 Gy).&#xD;
&#xD;
      Screening:&#xD;
&#xD;
      For all patients, OAB items of the USP scale will be completed before each standard weekly&#xD;
      assessment during prostate radiotherapy. Patients who reach an OAB sub-score greater to 5&#xD;
      will be addressed to an urologist in order to confirm absence of Qmax &lt; 10ml/sec at initial&#xD;
      assessment, or post-void residual urine &gt; 100 milliliter (ml).&#xD;
&#xD;
      Inclusion &amp; treatment:&#xD;
&#xD;
      A week at most after pre-screening, patients will be randomized to receive either&#xD;
      Vesicare®-5mg or a placebo. In both study arms, the treatment should be continued for 3&#xD;
      months.&#xD;
&#xD;
      Follow-up:&#xD;
&#xD;
      The radiation oncologist will perform patients' follow-up for the study at the treatment&#xD;
      initiation, 6 weeks and 3 months after start of the treatment (Vesicare or placebo).&#xD;
&#xD;
      The questionnaires for the evaluation of OAB syndrome, acute urinary toxicity and quality of&#xD;
      life should be completed for each follow-up visit. The voiding diary will be completed during&#xD;
      3 days before (or if not, 3 days after) all the evaluation times.&#xD;
&#xD;
      An urologist will perform an uroflowmetry and a post-voiding echography (or a bladder scan)&#xD;
      before initiation of the treatment, and after 6 weeks of treatment.&#xD;
&#xD;
      Statistics and sample size PATIENTS ENROLMENT 70 patients will be included (considering 66&#xD;
      patients completing the full study) within 3 recruitment centers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Target of recruitment not reachable&#xD;
  </why_stopped>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">July 15, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score of Urinary Symptom Profile (USP) questionnaire</measure>
    <time_frame>At 6 weeks</time_frame>
    <description>Score will be measured after study drug treatment initiation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Succinate of Solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of Succinate of Solifenacin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Succinate of Solifenacin</intervention_name>
    <arm_group_label>Succinate of Solifenacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Succinate of Solifenacin</intervention_name>
    <arm_group_label>Placebo of Succinate of Solifenacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prostate adenocarcinoma (histological confirmation),&#xD;
&#xD;
          -  Indication for prostate cancer radiotherapy (standard schema with a total dose from 70&#xD;
             to 80 Gray (GY)),&#xD;
&#xD;
          -  Patient affiliation to the French Social Security System,&#xD;
&#xD;
          -  Patient information and written informed consent,&#xD;
&#xD;
          -  Patient complaining of urinary symptoms during radiotherapy,&#xD;
&#xD;
          -  Occurrence of OverActive Bladder (OAB) subscore with the Urinary Symptom Profile (USP)&#xD;
             scale greater or equal to 5.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prostate irradiation contraindication&#xD;
&#xD;
          -  History of bladder or prostate surgery,&#xD;
&#xD;
          -  History of of pelvic radiotherapy,&#xD;
&#xD;
          -  Individual deprived of liberty or placed Under the authority of a tutor,&#xD;
&#xD;
          -  Age &lt; 18 years,&#xD;
&#xD;
          -  Flowmetry Qmax &lt; 10ml/s and/or post-void residual urine &gt; 100 ml (during urology&#xD;
             preinclusion visit)&#xD;
&#xD;
          -  Previous known OAB&#xD;
&#xD;
          -  Patients treated with non-authorized drugs,&#xD;
&#xD;
          -  Patients treated with anticholinergic or cholinesterase inhibitors within 12 months&#xD;
             before irradiation,&#xD;
&#xD;
          -  Patients treated with anticholinergic during and weeks following irradiation and&#xD;
             before Succinate of Solifenacin treatment start,&#xD;
&#xD;
          -  Patients treated with botulinum toxin within 9 months before screening,&#xD;
&#xD;
          -  Patients treated with alpha-blockers, 5-alpha reductase inhibitor within 12 months&#xD;
             preceding irradiation, during and weeks following irradiation and before Succinate of&#xD;
             Solifenacin treatment start,&#xD;
&#xD;
          -  Contraindication of Succinate of Solifenacin&#xD;
&#xD;
          -  Hypersensitivity or allergy to Solifenacin succinate or to any other antimuscarinic&#xD;
             agent,&#xD;
&#xD;
          -  Specific precautions of use for patients having decompensated urinary tract&#xD;
             obstruction at risk of urinary retention, vegetative neuropathy, long QT syndrome and&#xD;
             an hypokaliemia, history of long QT or patients at risk of QT prolongation,&#xD;
             obstructive gastrointestinal disorders.&#xD;
&#xD;
          -  Patients treated with oral biphosphonates, drugs that cause QT prolongation or by&#xD;
             substrates having affinity for CYP3A4 isoenzyme as verapamil and Diltiazem, or treated&#xD;
             with CYP3A4 inductors as rifampicin, phenytoin, carbamazepine&#xD;
&#xD;
          -  Galactose hereditary intolerance, lactase deficiency or a malabsorption syndrome of&#xD;
             glucose and galactose.&#xD;
&#xD;
          -  Patient enable to follow study medical care for family, social, geographical or&#xD;
             psychological reasons.&#xD;
&#xD;
          -  Participation to another clinical study on urinary toxicity and/or molecule that could&#xD;
             modify this toxicity and its evolution.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud de Crevoisier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugène Marquis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Pasteur Lanroze</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

